Home > Insider Trading > Filing (0001553878-16-000036)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1180432	John Maraganore	C/O Alnylam Pharmaceuticals, Inc. 300 Third Street Cambridge MA 02142	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-01-19	15,076	$22.75	148,465	No	4	M	Direct
Common Stock	Disposition	2016-01-19	1,838	$70.95	146,627	No	4	S	Direct
Common Stock	Disposition	2016-01-19	800	$71.81	145,827	No	4	S	Direct
Common Stock	Disposition	2016-01-19	1,281	$73.03	144,546	No	4	S	Direct
Common Stock	Disposition	2016-01-19	5,112	$74.14	139,434	No	4	S	Direct
Common Stock	Disposition	2016-01-19	3,400	$75.01	136,034	No	4	S	Direct
Common Stock	Disposition	2016-01-19	2,245	$75.97	133,789	No	4	S	Direct
Common Stock	Disposition	2016-01-19	200	$76.95	133,589	No	4	S	Direct
Common Stock	Disposition	2016-01-19	200	$78.04	133,389	No	4	S	Direct
Common Stock	Acquisiton	2016-01-20	15,076	$22.75	148,465	No	4	M	Direct
Common Stock	Disposition	2016-01-20	1,200	$66.28	147,265	No	4	S	Direct
Common Stock	Disposition	2016-01-20	2,700	$67.39	144,565	No	4	S	Direct
Common Stock	Disposition	2016-01-20	4,406	$68.35	140,159	No	4	S	Direct
Common Stock	Disposition	2016-01-20	2,114	$69.40	138,045	No	4	S	Direct
Common Stock	Disposition	2016-01-20	930	$70.43	137,115	No	4	S	Direct
Common Stock	Disposition	2016-01-20	1,136	$71.79	135,979	No	4	S	Direct
Common Stock	Disposition	2016-01-20	400	$72.51	135,579	No	4	S	Direct
Common Stock	Disposition	2016-01-20	1,865	$73.77	133,714	No	4	S	Direct
Common Stock	Disposition	2016-01-20	325	$74.61	133,389	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2016-01-19	15,076	$0.00	15,076	$22.75
Common Stock	Stock Option (Right to Buy)	Disposition	2016-01-20	15,076	$0.00	15,076	$22.75

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
105,529		2016-12-14	No	4	M	Direct
90,453		2016-12-14	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,750	Indirect	By Managed Account

Footnotes

All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2015. The 30,152 options exercised and sold by the reporting person were due to expire on December 14, 2016.
Sale prices ranged from $70.40 to $71.29.
Sale prices ranged from $71.41 to $72.34.
Sale prices ranged from $72.55 to $73.31.
Sale prices ranged from $73.60 to $74.59.
Sale prices ranged from $74.64 to $75.61.
Sale prices ranged from $75.76 to $76.65.
Sale prices ranged from $76.82 to $77.08.
Sale prices ranged from $78.01 to $78.07.
Sale prices ranged from $65.81 to $66.70.
Sale prices ranged from $66.81 to $67.70.
Sale prices ranged from $67.92 to $68.90.
Sale prices ranged from $69.00 to $69.98.
Sale prices ranged from $70.05 to $70.86.
Sale prices ranged from $71.06 to $72.02.
Sale prices ranged from $72.20 to $73.08.
Sale prices ranged from $73.38 to $74.28.
Sale prices ranged from $74.43 to $74.76.
The reporting person owns 2,750 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
The stock option vested as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares each successive three month period thereafter.